Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

Clinical Epigenetics

Volumn 2, Issue 2, 2011, Pages 389-399

  Kuendgen, Andrea ^a   Bug, Gesine ^b   Ottmann, Oliver G ^b   Haase, Detlef ^c   Schanz, Julie ^c   Hildebrandt, Barbara ^a   Nachtkamp, Kathrin ^a   Neukirchen, Judith ^a   Dienst, Ariane ^a   Haas, Rainer ^a   Germing, Ulrich ^a   Gattermann, Norbert ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CD34 ANTIGEN; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; MITOCHONDRIAL DNA; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLU LIKE SYNDROME; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; LEUKOCYTOSIS; LOCAL SKIN REACTION; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RISK BENEFIT ANALYSIS; SEPTICEMIA; SOMATIC MUTATION; SOMNOLENCE; SURVIVAL TIME; TREATMENT DURATION;

EID: 84856260226     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1007/s13148-011-0031-9     Document Type: Article

References (31)

1. Bennett JM, Catovsky D, Daniel MT et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199 (Pubitemid 12073508)
2. Bhalla KN (2005) Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23:3971-3993 (Pubitemid 46218700)
3. Braulke F, Schanz J, Jung K et al (2010) FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. Leuk Res 34:1296-1301
4. Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425 (Pubitemid 44061337)
5. Choi SH, Byun HM, Kwan JM, Issa JP, Yang AS (2007) Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol 138:616-623 (Pubitemid 47206723)
6. Craddock C, Goardon N, Griffiths M, Cavenagh JD, Siddique S, Vyas P (2008) 5' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells. ASH Annual Meeting Abstracts 112:945
7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223-232
8. Fenaux P, Mufti GJ, Hellström-Lindberg E et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562-569
9. Göttlicher M, Minucci S, Zhu P et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978 (Pubitemid 34062289)
10. Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088 (Pubitemid 27132124)
11. Grimwade D, Walker H, Oliver F et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333 (Pubitemid 28452973)
12. Harris NL, Jaffe ES, Diebold J et al (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10:1419-1432 (Pubitemid 30017051)
13. Issa JP, Castoro R, Ravandi-Kashani F et al (2008) Randomized phase II study of combined epigenetic therapy: decitabine vs. decitabine and valproic acid in MDS and AML. ASH Annual Meeting Abstracts 112:228
14. Itzykson R, Thepot S, Recher C et al (2009) Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program. ASH Annual Meeting Abstracts 114:1054
15. Kuendgen A, Strupp C, Aivado M et al (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266-1269 (Pubitemid 39166498)
16. Kuendgen A, Schmid M, Schlenk R et al (2006) The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106:112-119 (Pubitemid 43032555)
17. Kuendgen A, Gattermann N (2007) Valproic acid for the treatment of myeloid malignancies. Cancer 110:943-954 (Pubitemid 47312858)
18. Lubbert M, Schmid M, Ruter B et al (2008) Continued treatment with an outpatient maintenance schedule of decitabine in older AML patients ineligible for induction chemotherapy: results of the 00331 phase II multicenter trial. ASH Annual Meeting Abstracts 112:2965
19. Maurillo L, Spagnoli A, Genuardi M et al (2008) 5-Azacytidine for the treatment of acute myeloid leukemia: a retrospective, multicenter study of 55 patients. ASH Annual Meeting Abstracts 112:1947
20. Mufti GJ, Gore SD, Santini V et al (2009) Influence of karyotype on overall survival in patients with higher-risk myelodysplastic syndrome treated with azacitidine or a conventional care regimen. ASH Annual Meeting Abstracts 114:1755
21. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741
22. Raffoux E, Cras A, Recher C et al (2010) Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 1:34-42
23. Raj K, John A, Ho A et al (2007) CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 21:1937-1944 (Pubitemid 47299967)
24. Silverman LR, Holland JF, Demakos EP et al (1994) Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol 68:A12 (meeting abstract)
25. Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440 (Pubitemid 34525728)
26. Silverman LR, McKenzie DR, Peterson BL et al (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol 24:3895-3903 (Pubitemid 46630737)
27. Soriano AO, Yang H, Faderl S et al (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302-2308 (Pubitemid 47523148)
28. Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J (2006) Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 107:1839-1843 (Pubitemid 44582953)
29. Voso MT, Santini V, Finelli C et al (2009) Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 15:5002-5007
30. Wulfert M, Küpper AC, Tapprich C et al (2008) Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol 36:577-586 (Pubitemid 351551472)
31. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G (2005) Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res 29:739-748 (Pubitemid 40779480)